Browsing Tag
biosimilars
17 posts
Dr. Reddy’s (NSE: DRREDDY) signals dual-track U.S. growth strategy with abatacept biosimilar BLA acceptance and OTC eye-care expansion
Discover how Dr. Reddy’s FDA-accepted abatacept biosimilar and OTC eye-care launch are reshaping its U.S. growth and investor outlook.
Is Orencia finally vulnerable? Dr. Reddy’s abatacept biosimilar clears a key FDA hurdle
Dr. Reddy’s abatacept biosimilar enters FDA review. See what this means for Orencia, biosimilar policy, and U.S. autoimmune drug pricing.
Viatris (Nasdaq: VTRS) exits Biocon Biologics with $815m deal as biosimilars reentry accelerates
Viatris unlocks $815M from Biocon Biologics exit and regains biosimilars access. Find out how this reshapes its 2026 global pharma strategy.
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A
EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.
Prolia and Xgeva just got rivals: FDA clears BILDYOS and BILPREVDA biosimilars for U.S. launch
The FDA has approved Henlius and Organon’s denosumab biosimilars. Find out what this means for U.S. bone health access, pricing, and investor sentiment.
Sagent Pharmaceuticals and Qilu Pharmaceutical sign $4.5bn injectable drug deal to boost U.S. hospital supply access
Sagent Pharmaceuticals signs $4.5B deal with Qilu Pharmaceutical to boost U.S. access to complex injectable drugs, improving affordability and supply resilience.
Biocon (NSE: BIOCON) gains EU nod for Denosumab biosimilars Vevzuo and Evfraxy to target bone health market
Biocon Biologics receives EU approval for Denosumab biosimilars Vevzuo and Evfraxy. Find out how this milestone could reshape its European biosimilars strategy.
Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?
Explore Dr. Reddy’s biosimilars pipeline, regulatory milestones, and commercial strategy—can it compete with Biocon and global pharma giants in 2025?